ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Testosterone Replacement Does Not Cause Priaprism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 762" data-attributes="member: 3"><p>We have all watched TV advertisement for Viagra and Cialis in which they mention the risk of priaprism (prolonged erections for more than 1 hour). I really think that rare side effect is used to lead men to believe that they will have long acting erections when taking those ED drugs.</p><p></p><p>This study found not a single case of priaprism in men using a T gel.</p><p></p><p></p><p>[ATTACH]200[/ATTACH]</p><p></p><p><a href="http://www.ncbi.nlm.nih.gov/pubmed/23347341#" target="_blank">J Sex Med.</a> 2013 Apr;10(4):1151-61. doi: 10.1111/jsm.12059. Epub 2013 Jan 24.</p><p><strong>Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship.</strong></p><p></p><p><a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Burnett%20AL%5BAuthor%5D&cauthor=true&cauthor_uid=23347341" target="_blank">Burnett AL</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kan-Dobrosky%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23347341" target="_blank">Kan-Dobrosky N</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=Miller%20MG%5BAuthor%5D&cauthor=true&cauthor_uid=23347341" target="_blank">Miller MG</a>.</p><p><strong>Source</strong></p><p></p><p>James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-2101, USA. <a href="mailto:aburnet1@jhmi.edu">aburnet1@jhmi.edu</a></p><p></p><p><strong>Abstract</strong></p><p></p><p><strong>INTRODUCTION:</strong></p><p></p><p>Although testosterone replacement therapy (TRT) is the preferred treatment for hypogonadism, information for patients using testosterone includes too frequent or prolonged erections as a potential side effect.</p><p><strong>AIM:</strong></p><p></p><p>To assess the frequency and risk of priapism or related adverse events (AEs) in hypogonadal men treated with a 1% testosterone gel.</p><p><strong>METHODS:</strong></p><p></p><p>Safety and tolerability data for AndroGel 1% were assessed, including three randomized, controlled clinical trials in varying populations of hypogonadal or near hypogonadal men. Study 1 was a Phase 3 trial of AndroGel 1% 5&#8201;g, 7.5&#8201;g, or 10&#8201;g once daily for 6 months (N&#8201;=&#8201;227). Study 2 was a Phase 2 trial of AndroGel 1% 7.5&#8201;g once daily titrated as needed vs. placebo for 26 weeks in men with type 2 diabetes (N&#8201;=&#8201;180). Study 3 was a Phase 4 trial of AndroGel 1% 5&#8201;g once daily vs. placebo for 12 weeks in men previously unresponsive to sildenafil 100&#8201;mg monotherapy and receiving concomitant sildenafil 100&#8201;mg (N&#8201;=&#8201;75). Postmarketing AndroGel pharmacovigilance reporting data from 2001 to 2011 was searched for events coded as priapism.</p><p><strong>MAIN OUTCOME MEASURES:</strong></p><p></p><p>The incidence of priapism and/or related symptoms reported as urogenital or reproductive system AEs.</p><p><strong>RESULTS:</strong></p><p></p><p>In the 283 men exposed to AndroGel 1% over the three trials, mean exposure ranged from 84 days to 149 days. No AEs described as priapism or related symptoms were reported in the three trials. In the postmarketing data, representing 40 million units sold, eight cases described as priapism were reported. Of the six cases with accompanying data, all were judged as possibly related to AndroGel.</p><p><strong>CONCLUSIONS:</strong></p><p></p><p>Safety data from the clinical trials for AndroGel 1% did not report any cases of priapism, and its incidence in the postmarketing pharmacovigilance data is extremely low, indicating a minimal risk of inducing priapism.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 762, member: 3"] We have all watched TV advertisement for Viagra and Cialis in which they mention the risk of priaprism (prolonged erections for more than 1 hour). I really think that rare side effect is used to lead men to believe that they will have long acting erections when taking those ED drugs. This study found not a single case of priaprism in men using a T gel. [ATTACH=CONFIG]200[/ATTACH] [URL="http://www.ncbi.nlm.nih.gov/pubmed/23347341#"]J Sex Med.[/URL] 2013 Apr;10(4):1151-61. doi: 10.1111/jsm.12059. Epub 2013 Jan 24. [B]Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship.[/B] [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=Burnett%20AL%5BAuthor%5D&cauthor=true&cauthor_uid=23347341"]Burnett AL[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=Kan-Dobrosky%20N%5BAuthor%5D&cauthor=true&cauthor_uid=23347341"]Kan-Dobrosky N[/URL], [URL="http://www.ncbi.nlm.nih.gov/pubmed?term=Miller%20MG%5BAuthor%5D&cauthor=true&cauthor_uid=23347341"]Miller MG[/URL]. [B]Source[/B] James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-2101, USA. [EMAIL="aburnet1@jhmi.edu"]aburnet1@jhmi.edu[/EMAIL] [B]Abstract[/B] [B]INTRODUCTION:[/B] Although testosterone replacement therapy (TRT) is the preferred treatment for hypogonadism, information for patients using testosterone includes too frequent or prolonged erections as a potential side effect. [B]AIM:[/B] To assess the frequency and risk of priapism or related adverse events (AEs) in hypogonadal men treated with a 1% testosterone gel. [B]METHODS:[/B] Safety and tolerability data for AndroGel 1% were assessed, including three randomized, controlled clinical trials in varying populations of hypogonadal or near hypogonadal men. Study 1 was a Phase 3 trial of AndroGel 1% 5 g, 7.5 g, or 10 g once daily for 6 months (N = 227). Study 2 was a Phase 2 trial of AndroGel 1% 7.5 g once daily titrated as needed vs. placebo for 26 weeks in men with type 2 diabetes (N = 180). Study 3 was a Phase 4 trial of AndroGel 1% 5 g once daily vs. placebo for 12 weeks in men previously unresponsive to sildenafil 100 mg monotherapy and receiving concomitant sildenafil 100 mg (N = 75). Postmarketing AndroGel pharmacovigilance reporting data from 2001 to 2011 was searched for events coded as priapism. [B]MAIN OUTCOME MEASURES:[/B] The incidence of priapism and/or related symptoms reported as urogenital or reproductive system AEs. [B]RESULTS:[/B] In the 283 men exposed to AndroGel 1% over the three trials, mean exposure ranged from 84 days to 149 days. No AEs described as priapism or related symptoms were reported in the three trials. In the postmarketing data, representing 40 million units sold, eight cases described as priapism were reported. Of the six cases with accompanying data, all were judged as possibly related to AndroGel. [B]CONCLUSIONS:[/B] Safety data from the clinical trials for AndroGel 1% did not report any cases of priapism, and its incidence in the postmarketing pharmacovigilance data is extremely low, indicating a minimal risk of inducing priapism. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Testosterone Replacement Does Not Cause Priaprism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top